The Baker Bros. buy signals confidence from the largest holder, but the CEO/CFO/CMO/CAO selling, especially the CEO's $510K sale on the offering pricing date, is a cautionary signal. Monitor for additional insider sales in the next 30 days; if C-suite selling continues above $1M total, it would suggest insiders are taking advantage of the post-approval pop. The TUDRIQEV launch and IGNYTE-3 confirmatory trial data are the next catalysts.
Drug in focus
REPL drug pipeline →TUDRIQEV
● Neutral Named in this insider cluster- Impact
- Phase
- Approved (Accelerated Approval)
- Time to market
- Already approved and commercially available in the U.S. since October 2026.
- Next catalyst
- None dated
What to watchTUDRIQEV is now a commercial-stage asset, so the focus shifts from regulatory binary to revenue execution. Watch the next quarterly earnings (likely late January 2027) for early sales figures, formulary adoption metrics, and the permanent J-code expected by April 2027. The confirmatory Phase 3 trial data timeline is the next major binary but has no announced readout date yet.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 20 $14.05entry
- T+1 · 3mo ago +5.12%α +4.72% · $14.77
- T+5 · 3mo ago +11.03%α +9.92% · $15.60
- T+20 · 2mo ago −6.98%α −6.98% · $13.07
- T+60 · 4d ago +55.80%α +56.88% · $21.89
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Replimune insiders show a mixed cluster: Baker Bros. (10% owner) bought $1.52M in the public offering at $12.06, while the CEO, CFO, CMO, and CAO collectively sold $889K in open-market sales. The CEO/CMO/CAO sales on 8/10 coincided with the $150M dilutive offering priced at $12.06, and the CFO's sale on 8/17 followed the stock's rise to $14.28 after the FDA approval of TUDRIQEV. The Baker Bros. buy is a strong vote of confidence from the largest holder, but the C-suite selling, especially the CEO's $510K sale, creates a bearish signal that partially offsets the bullish approval catalyst.
Key Financial Metrics
Key Facts
- Baker Bros. Advisors LP (10% owner) bought 126,400 shares at $12.06 for $1.52M on 8/11, participating in the $150M public offering.
- CEO Sushil Patel sold 39,300 shares at $12.97 for $510K on 8/10, the same day the $150M offering was priced.
- CFO Emily Luisa Hill sold 9,256 shares at $14.28 for $132K on 8/17, after the stock rose post-FDA approval.
- CMO Konstantinos Xynos sold 11,400 shares at $12.97 for $148K on 8/10.
- CAO Andrew Schwendenman sold 7,600 shares at $12.97 for $99K on 8/10.
- Total insider open-market sales: $889K; total insider buy: $1.52M; net cluster value: +$631K (buy-side).
- The $150M offering (424B5) closed 9 days prior, diluting existing shareholders by ~13%.
- FDA accelerated approval of TUDRIQEV (RP1) was granted on 8/6/2026, transforming Replimune into a commercial-stage biotech.
Financial Impact
Insider cluster net buy of $631K, but C-suite sales of $889K (0.06% of $1.5B market cap) are modest in size. The $150M offering represents ~13% dilution.
Risk Factors
- C-suite selling (CEO, CFO, CMO, CAO) within days of FDA approval and a dilutive offering suggests insiders may view the current valuation as a selling opportunity.
- The $150M offering diluted existing shareholders by ~13%, and the company has never generated product revenue.
- TUDRIQEV's accelerated approval requires confirmatory trial (IGNYTE-3) data; failure could lead to withdrawal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-REPL-1787180496366 |
Track record
32 reports on REPL
9 of 13 bullish or bearish reports moved the stock their way by T+60. Best: +188.35% at T+20 after the Jul 30, 2026 report. 13 of 14 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $21.90 Now $21.41 −2.24% settles Feb 12
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $21.78 Now $21.41 −1.70% settles Feb 9
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 6, 202610d ago 10-Q/A Neutral 3/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 Entry $20.69 Now $21.41 −3.48% settles Feb 2
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.69 Now $21.41 +3.48% settles Feb 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $20.65 Now $21.41 +3.68% settles Feb 1
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $19.49 Now $21.41 +9.85% settles Jan 29
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers